Travere Therapeutics names Bradley Campbell CEO as Eric Dube exits
Dube will leave Travere's top job and board seat on December 1, 2026, handing the CEO role to former Amicus Therapeutics chief Bradley Campbell.
SEC filing
Latest
3 stories
Monday, September 21
Tuesday, August 4
Travere reports Q2 2026 results as FSGS launch begins and civorebrutinib deal closes
FILSPARI's FSGS launch and IgAN demand drove sales growth as pegtibatinase enrollment continues and civorebrutinib joins the pipeline.
SEC filing
Thursday, July 9
Travere's chief accounting officer to retire, controller named as successor
Sandra Calvin plans to step down as CAO and PAO after filing the 2027 annual report, with John Torell expected to take.
SEC filing